ABSTRACT
PURPOSE: To investigate the effect of intrathecal administration of CCPA, an adenosine A1 receptor agonist, on voiding function in rats with cystitis induced by cyclophosphamide (CYP). METHODS: Thirty 8-week-old Sprague Dawley rats were randomly divided into a control group (n = 15) and a cystitis group (n = 15). Cystitis was induced by a single intraperitoneal injection of CYP (200 mg/kg, dissolved in physiological saline) in rats. Control rats were injected intraperitoneally with physiological saline. The PE10 catheter reached the level of L6-S1 spinal cord through L3-4 intervertebral space for intrathecal injection. Forty-eight hours after intraperitoneal injection, urodynamic tests were conducted to observe the effect of intrathecal administration of 10% dimethylsulfoxide (vehicle) and 1 nmol CCPA on micturition parameters, including basal pressure (BP), threshold pressure (TP), maximal voiding pressure (MVP), intercontraction interval (ICI), voided volume (VV), residual volume (RV), bladder capacity (BC), and voiding efficiency (VE). Histological changes of the bladder of cystitis rats were studied through hematoxylin-eosin staining (HE staining). Moreover, Western blot and immunofluorescence were used to study the expression of adenosine A1 receptor in the L6-S1 dorsal spinal cord in both groups of rats. RESULTS: HE staining revealed submucosal hemorrhage, edema, and inflammatory cell infiltration in the bladder wall of cystitis rats. The urodynamic test showed significant increase in BP, TP, MVP and RV in cystitis rats, while ICI, VV, BC and VE decreased significantly, indicating bladder overactivity. CCPA inhibited the micturition reflex in both control and cystitis rats, and significantly increased TP, ICI, VV, BC, and VE, but had no significant effect on BP, MVP and RV. Western blot and immunofluorescence showed that there was no significant difference in the expression of adenosine A1 receptor in the L6-S1 dorsal spinal cord between the control and cystitis rats. CONCLUSION: The findings of this study suggest that intrathecal administration of the adenosine A1 receptor agonist CCPA alleviates CYP-induced bladder overactivity. Furthermore, our results indicate that the adenosine A1 receptor in the lumbosacral spinal cord may be a promising target for treatment of bladder overactivity.
Subject(s)
Cystitis , Urinary Bladder, Overactive , Rats , Animals , Urinary Bladder/pathology , Receptor, Adenosine A1/metabolism , Rats, Sprague-Dawley , Urinary Bladder, Overactive/chemically induced , Urinary Bladder, Overactive/drug therapy , Urinary Bladder, Overactive/metabolism , Adenosine A1 Receptor Agonists/adverse effects , Adenosine A1 Receptor Agonists/metabolism , Cystitis/chemically induced , Cystitis/complications , Cystitis/drug therapy , Cyclophosphamide/toxicity , Spinal Cord/metabolismABSTRACT
Partial agonists for G protein-coupled receptors (GPCRs) provide opportunities for novel pharmacotherapies with enhanced on-target safety compared to full agonists. For the human adenosine A1 receptor (hA1AR) this has led to the discovery of capadenoson, which has been in phase IIa clinical trials for heart failure. Accordingly, the design and profiling of novel hA1AR partial agonists has become an important research focus. In this study, we report on LUF7746, a capadenoson derivative bearing an electrophilic fluorosulfonyl moiety, as an irreversibly binding hA1AR modulator. Meanwhile, a nonreactive ligand bearing a methylsulfonyl moiety, LUF7747, was designed as a control probe in our study. In a radioligand binding assay, LUF7746's apparent affinity increased to nanomolar range with longer pre-incubation time, suggesting an increasing level of covalent binding over time. Moreover, compared to the reference full agonist CPA, LUF7746 was a partial agonist in a hA1AR-mediated G protein activation assay and resistant to blockade with an antagonist/inverse agonist. An in silico structure-based docking study combined with site-directed mutagenesis of the hA1AR demonstrated that amino acid Y2717.36 was the primary anchor point for the covalent interaction. Additionally, a label-free whole-cell assay was set up to identify LUF7746's irreversible activation of an A1 receptor-mediated cell morphological response. These results led us to conclude that LUF7746 is a novel covalent hA1AR partial agonist and a valuable chemical probe for further mapping the receptor activation process. It may also serve as a prototype for a therapeutic approach in which a covalent partial agonist may cause less on-target side effects, conferring enhanced safety compared to a full agonist.
Subject(s)
Adenosine A1 Receptor Agonists/metabolism , Adenosine A1 Receptor Agonists/pharmacology , Drug Design , Drug Partial Agonism , Receptor, Adenosine A1/metabolism , Adenosine A1 Receptor Agonists/chemistry , Animals , CHO Cells , Cricetinae , Cricetulus , Dose-Response Relationship, Drug , HEK293 Cells , Humans , Protein Structure, Secondary , Radioligand Assay/methods , Receptor, Adenosine A1/chemistryABSTRACT
Elevated circulating free fatty acid (FFA) level is closely linked to the pathogenesis of insulin resistance and type 2 diabetes mellitus. Activation of the adenosine A1 receptor (A1R) inhibits lipolysis in adipocytes and hence reduces the concentration of FFA, which represents a potential target for the development of antilipolytic agents. We aimed to assess the binding affinity as well as target binding kinetics of A1R agonists and further delineate a possible relationship with their antilipolytic effect in adipocytes. Radioligand binding assays were performed to determine the affinity and kinetics of three representative A1R agonists, namely CPA, LUF6944 and LUF6941, on the rat A1R. Functional responses to these agonists were examined in both a recombinant cell system and physiologically relevant rat adipocytes. The three A1R agonists displayed similar affinity while divergent target binding kinetics on the rat A1R. Irrespective of equilibrium binding affinity, temporal analysis of receptor signaling demonstrated persistent functional responses for the long residence time agonist, despite removal of excess agonist, in both a recombinant cell system and in rat adipocytes. By contrast, such effect was less pronounced or even lost for agonists with medium or short receptor residence time, respectively. Our results indicate that ligand receptor binding kinetics rather than their affinity or potency play an essential role in regulating cellular responses. The long residence time A1R agonist produces a sustained wash-resistant antilipolytic effect in rat adipocytes and thus may represent a potential antilipolytic alternative for further investigation.
Subject(s)
Adenosine A1 Receptor Agonists/administration & dosage , Adenosine A1 Receptor Agonists/metabolism , Adipocytes/drug effects , Adipocytes/metabolism , Lipolysis/drug effects , Animals , CHO Cells , Cricetinae , Cricetulus , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/metabolism , Dose-Response Relationship, Drug , Lipolysis/physiology , RatsABSTRACT
Central adenosine A1 receptor (A1R) is implicated in pain, sleep, substance use disorders, and neurodegenerative diseases, and is an important target for pharmaceutical development. Radiotracers for A1R positron emission tomography (PET) would enable measurement of the dynamic interaction of endogenous adenosine and A1R during the sleep-awake cycle. Although several human A1R PET tracers have been developed, most are xanthine-based antagonists that failed to demonstrate competitive binding against endogenous adenosine. Herein, we explored non-nucleoside (3,5-dicyanopyridine and 5-cyanopyrimidine) templates for developing an agonist A1R PET radiotracer. We synthesized novel analogues, including 2-amino-4-(3-methoxyphenyl)-6-(2-(6-methylpyridin-2-yl)ethyl)pyridine-3,5-dicarbonitrile (MMPD, 22b), a partial A1R agonist of sub-nanomolar affinity. [11C]22b showed suitable blood-brain barrier (BBB) permeability and test-retest reproducibility. Regional brain uptake of [11C]22b was consistent with known brain A1R distribution and was blocked significantly by A1R but not A2AR ligands. [11C]22b is the first BBB-permeable A1R partial agonist PET radiotracer with the promise of detecting endogenous adenosine fluctuations.
Subject(s)
Adenosine A1 Receptor Agonists/metabolism , Positron-Emission Tomography , Receptor, Adenosine A1/metabolism , Adenosine A1 Receptor Agonists/chemistry , Blood-Brain Barrier/metabolism , HEK293 Cells , Humans , Ligands , Structure-Activity RelationshipABSTRACT
Organophosphorus nerve agents (NAs) irreversibly inhibit acetylcholinesterase (AChE), the enzyme responsible for breaking down the neurotransmitter acetylcholine (ACh). The over accumulation of ACh after NA exposure leads to cholinergic toxicity, seizure, and death. Current medical countermeasures effectively mitigate peripheral symptoms, however; the brain is often unprotected. Alternative acute treatment with the adenosine A1 receptor agonist N6-cyclopentyladensosine (CPA) has previously been demonstrated to prevent AChE inhibition as well as to suppress neuronal activity. The mechanism of AChE protection is unknown. To elucidate the feasibility of potential CPA-AChE interaction mechanisms, we applied a truncated molecular model approach and density functional theory. The candidate mechanisms studied are reversible enzyme inhibition, enzyme reactivation, and NA blocking prior to enzyme conjugation. Our thermodynamic data suggest that CPA can compete with the NAs sarin and soman for the active site of AChE, but may, in contrast to NAs, undergo back-reaction. We found a strong interaction between CPA and NA conjugated AChE, making enzyme reactivation unlikely but possibly allowing for CPA protection through the prevention of NA aging. The data also indicates that there is an affinity between CPA and unbound NAs. The results from this study support the hypothesis that CPA counters NA toxicity via multiple mechanisms and is a promising therapeutic strategy that warrants further development.
Subject(s)
Acetylcholinesterase/metabolism , Adenosine A1 Receptor Agonists/metabolism , Adenosine/analogs & derivatives , Nerve Agents/metabolism , Organophosphorus Compounds/metabolism , Sarin/metabolism , Soman/metabolism , Adenosine/chemistry , Adenosine/metabolism , Adenosine/pharmacology , Adenosine A1 Receptor Agonists/chemistry , Adenosine A1 Receptor Agonists/pharmacology , Animals , Molecular Structure , Nerve Agents/chemistry , Nerve Agents/pharmacology , Organophosphorus Compounds/chemistry , Organophosphorus Compounds/pharmacology , Quantum Theory , Rats , Sarin/chemistry , Sarin/pharmacology , Soman/chemistry , Soman/pharmacology , ThermodynamicsABSTRACT
Our previous work discovered that combining the appropriate 5'- and N6-substitution in adenosine derivatives leads to the highly selective human A1 adenosine receptor (hA1AR) agonists or highly potent dual hA1AR agonists and hA3AR antagonists. In order to explore novel dual adenosine receptor ligands, a series of N6-substituted-5'-pyrazolyl-adenosine and 2-chloro-adenosine derivatives were synthesized and assayed in vitro at all ARs. The N6-(±)-endo-norbornyl derivative 12 was the most potent and selective at A1AR and effective as an analgesic in formalin test in mice, but none of the 5'-pyrazolyl series compounds showed a dual behavior at hA1 and hA3AR. Molecular modeling studies rationalized the structure-activity relationships and the selectivity profiles of the new series of A1AR agonists. Interestingly, an unexpected inverted binding mode of the N6-tetrahydrofuranyl derivative 14 was hypothesized to explain its low affinity at A1AR.
Subject(s)
Adenosine/chemical synthesis , Adenosine/pharmacology , Drug Design , Receptor, Adenosine A1/metabolism , Adenosine/chemistry , Adenosine/metabolism , Adenosine A1 Receptor Agonists/chemical synthesis , Adenosine A1 Receptor Agonists/chemistry , Adenosine A1 Receptor Agonists/metabolism , Adenosine A1 Receptor Agonists/pharmacology , Adenylyl Cyclases/metabolism , Analgesics/chemical synthesis , Analgesics/chemistry , Analgesics/metabolism , Analgesics/pharmacology , Animals , Chemistry Techniques, Synthetic , Male , Mice , Molecular Docking Simulation , Protein Conformation , Receptor, Adenosine A1/chemistry , Structure-Activity RelationshipABSTRACT
Three 4-amino-6-alkyloxy-2-alkylthiopyrimidine derivatives (4-6) were investigated as potential non-nucleoside agonists at human adenosine receptors (ARs). When tested in competition binding experiments, these compounds exhibited low micromolar affinity (Ki values comprised between 1.2 and 1.9 µm) for the A1 AR and no appreciable affinity for the A2A and A3 ARs. Evaluation of their efficacy profiles by measurement of intracellular cAMP levels revealed that 4 and 5 behave as non-nucleoside agonists of the A1 AR with EC50 values of 0.47 and 0.87 µm, respectively. No clear concentration-response curves could be instead obtained for 6, probably because this compound modulates one or more additional targets, thus masking the putative effects exerted by its activation of A1 AR. The three compounds were not able to modulate A2B AR-mediated cAMP accumulation induced by the non-selective AR agonist NECA, thus demonstrating no affinity toward this receptor.
Subject(s)
Adenosine A1 Receptor Agonists/chemistry , Pyrimidines/chemistry , Receptor, Adenosine A1/metabolism , Adenosine A1 Receptor Agonists/chemical synthesis , Adenosine A1 Receptor Agonists/metabolism , Adenosine A1 Receptor Agonists/pharmacology , Animals , CHO Cells , Cricetinae , Cricetulus , Cyclic AMP/metabolism , Humans , Protein Binding , Protein Isoforms/agonists , Protein Isoforms/genetics , Protein Isoforms/metabolism , Pyrimidines/chemical synthesis , Pyrimidines/metabolism , Pyrimidines/pharmacology , Receptor, Adenosine A1/chemistry , Receptor, Adenosine A1/genetics , Signal Transduction/drug effectsSubject(s)
Disease Models, Animal , Drug Discovery/methods , Glaucoma/drug therapy , Adenosine A1 Receptor Agonists/administration & dosage , Adenosine A1 Receptor Agonists/metabolism , Animals , Glaucoma/metabolism , Humans , Intraocular Pressure/drug effects , Intraocular Pressure/physiology , MiceABSTRACT
By means of guanosine-5'-O-(3-[(35)S]thio)triphosphate ([(35)S]GTPγS) binding assay combined with immunoprecipitation using anti-Gα subunit antibody, we recently reported 5-HT2A receptor- and M1 muscarinic acetylcholine receptor-mediated Gαq activation in rat cerebral cortical membranes (Odagaki et al., 2014). In the present study, this method has been applied to postmortem human brains, with focusing on adenosine receptor-mediated G-protein activation. In the exploratory experiments using a series of agonists and the antibodies specific to each Gα subtypes in the presence of low (10 nM) or high (50 µM) concentration of GDP, the most prominent increases in specific [(35)S]GTPγS binding in the membranes prepared from human prefrontal cortex were obtained for the combinations of adenosine (1mM)/anti-Gαi-3 in the presence of 50 µM GDP as well as 5-HT (100 µM)/anti-Gαq and carbachol (1mM)/anti-Gαq in the presence of 10nM GDP. Adenosine-induced activation of Gαi-3 emerged only when GDP concentrations were increased higher than 10 µM, and the following experiments were performed in the presence of 300 µM GDP. Adenosine increased specific [(35)S]GTPγS binding to Gαi-3 in a concentration-dependent manner to 251.4% of the basal unstimulated binding, with an EC50 of 1.77 µM. The involvement of adenosine A1 receptor was verified by the experiments using selective agonists and antagonists at adenosine A1 or A3 receptor. Among the α subunits of Gi/o class (Gαi-1, Gαi-2, Gαi-3, and Gαo.), only Gαi-3 was activated by 1mM adenosine, indicating that human brain adenosine A1 receptor is coupled preferentially, if not exclusively, to Gαi-3.
Subject(s)
GTP-Binding Protein alpha Subunits, Gi-Go/metabolism , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Immunoprecipitation , Prefrontal Cortex/metabolism , Receptor, Adenosine A1/metabolism , Adenosine/metabolism , Adenosine A1 Receptor Agonists/metabolism , Adenosine A1 Receptor Agonists/pharmacology , Adenosine A1 Receptor Antagonists/metabolism , Adenosine A1 Receptor Antagonists/pharmacology , Adolescent , Adult , Aged , Aged, 80 and over , Autopsy , Binding, Competitive , Dose-Response Relationship, Drug , Female , Guanosine Diphosphate/metabolism , Humans , Male , Middle Aged , Prefrontal Cortex/drug effects , Protein Binding , Receptor, Adenosine A1/drug effects , Young AdultABSTRACT
Adenosine receptors (ARs) have emerged as new drug targets. The majority of data on affinity/potency and selectivity of AR ligands described in the literature has been obtained for the human species. However, preclinical studies are mostly performed in mouse or rat, and standard AR agonists and antagonists are frequently used for studies in rodents without knowing their selectivity in the investigated species. In the present study, we selected a set of frequently used standard AR ligands, 8 agonists and 16 antagonists, and investigated them in radioligand binding studies at all four AR subtypes, A1, A2A, A2B, and A3, of three species, human, rat, and mouse. Recommended, selective agonists include CCPA (for A1AR of rat and mouse), CGS-21680 (for A2A AR of rat), and Cl-IB-MECA (for A3AR of all three species). The functionally selective partial A2B agonist BAY60-6583 was found to additionally bind to A1 and A3AR and act as an antagonist at both receptor subtypes. The antagonists PSB-36 (A1), preladenant (A2A), and PSB-603 (A2B) displayed high selectivity in all three investigated species. MRS-1523 acts as a selective A3AR antagonist in human and rat, but is only moderately selective in mouse. The comprehensive data presented herein provide a solid basis for selecting suitable AR ligands for biological studies.
Subject(s)
Receptors, Purinergic P1/drug effects , Adenosine A1 Receptor Agonists/metabolism , Adenosine A1 Receptor Agonists/pharmacology , Adenosine A1 Receptor Antagonists/metabolism , Adenosine A1 Receptor Antagonists/pharmacology , Adenosine A2 Receptor Agonists/metabolism , Adenosine A2 Receptor Agonists/pharmacology , Adenosine A2 Receptor Antagonists/metabolism , Adenosine A2 Receptor Antagonists/pharmacology , Adenosine A3 Receptor Agonists/metabolism , Adenosine A3 Receptor Agonists/pharmacology , Adenosine A3 Receptor Antagonists/metabolism , Adenosine A3 Receptor Antagonists/pharmacology , Animals , Arrestin/metabolism , Binding, Competitive/drug effects , CHO Cells , Cell Membrane/drug effects , Cell Membrane/metabolism , Cricetinae , Cricetulus , Cyclic AMP/metabolism , DNA, Complementary/drug effects , DNA, Complementary/genetics , Humans , Mice , Rats , Receptor, Adenosine A2A/drug effects , Receptor, Adenosine A2A/genetics , Receptor, Adenosine A2A/metabolism , Receptor, Adenosine A2B/drug effects , Receptor, Adenosine A2B/genetics , Receptor, Adenosine A2B/metabolism , Receptors, Purinergic P1/genetics , Receptors, Purinergic P1/metabolism , Species Specificity , Structure-Activity RelationshipABSTRACT
We report the synthesis and evaluation of previously unreported 4-amino-6-aryl-5-cyano-2-thiopyrimidines as selective human adenosine A1 receptor (hA1AR) agonists with tunable binding kinetics, this without affecting their nanomolar affinity for the target receptor. They show a very diverse range of kinetic profiles (from 1 min (compound 52) to 1 h (compound 43)), and their structure-affinity relationships (SAR) and structure-kinetics relationships (SKR) were established. When put in perspective with the increasing importance of binding kinetics in drug discovery, these results bring new evidence of the consequences of affinity-only driven selection of drug candidates, that is, the potential elimination of slightly less active compounds that may display preferable binding kinetics.
Subject(s)
Adenosine A1 Receptor Agonists/chemical synthesis , Pyrimidines/chemical synthesis , Adenosine A1 Receptor Agonists/metabolism , Adenosine A1 Receptor Agonists/pharmacology , Animals , CHO Cells , Cricetulus , Drug Discovery , HEK293 Cells , Humans , Pyrimidines/metabolism , Pyrimidines/pharmacology , Radioligand Assay , Structure-Activity RelationshipABSTRACT
AIMS: We previously observed that the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) is a very effective antinociceptive agent on intact but not on spinalized adult rats with inflammation. Since a close connection between opioid and adenosine A1 receptors has been described, we studied a possible relationship between these systems in the spinal cord. MAIN METHODS: CPA-mediated antinociception was challenged by the selective adenosine A1 receptor antagonist 8-cyclopentyl-1, 3-dimethylxanthine (CPT) and by the opioid receptor antagonist naloxone on male adult Wistar rats with carrageenan-induced inflammation. Withdrawal reflexes activated by noxious mechanical and electrical stimulation were recorded using the single motor technique in intact and sham-spinalized animals. KEY FINDINGS: CPA was very effective in intact and sham spinalized rats but not in spinalized animals. Full reversal of CPA antinociception was observed with i.v. 1mg/kg of naloxone but not with 20mg/kg of CPT i.v. in responses to noxious mechanical and electrical stimulation. CPT fully prevented CPA from any antinociceptive action whereas naloxone did not modify CPA activity. These results suggest a centrally-mediated action, since CPA depressed the wind-up phenomenon which is derived of the activity of spinal cord neurons. SIGNIFICANCE: The present study provides strong in vivo evidence of an antinociceptive activity mediated by the adenosine A1 receptor system in the spinal cord, linked to an activation of opioid receptors in adult animals with inflammation.
Subject(s)
Adenosine A1 Receptor Agonists/metabolism , Adenosine/analogs & derivatives , Pain/metabolism , Receptor, Adenosine A1/metabolism , Receptors, Opioid/metabolism , Spinal Cord/metabolism , Adenosine/metabolism , Adenosine/pharmacology , Adenosine/therapeutic use , Adenosine A1 Receptor Agonists/pharmacology , Adenosine A1 Receptor Agonists/therapeutic use , Animals , Inflammation/drug therapy , Inflammation/metabolism , Inflammation/pathology , Male , Pain/drug therapy , Pain/pathology , Pain Measurement/drug effects , Pain Measurement/methods , Rats , Rats, Wistar , Reflex/drug effects , Reflex/physiology , Spinal Cord/drug effects , Spinal Cord/pathologyABSTRACT
Using bioluminescence resonance energy transfer and proximity ligation assays, we obtained the first direct evidence that adenosine A1 receptors (A1Rs) form homomers not only in cell cultures but also in brain cortex. By radioligand binding experiments in the absence or in the presence of the A1Rs allosteric modulator, adenosine deaminase, and by using the two-state dimer receptor model to fit binding data, we demonstrated that the protomer-protomer interactions in the A1R homomers account for some of the pharmacological characteristics of agonist and antagonist binding to A1Rs. These pharmacological properties include the appearance of cooperativity in agonist binding, the change from a biphasic saturation curve to a monophasic curve in self-competition experiments and the molecular cross-talk detected when two different specific molecules bind to the receptor. In this last case, we discovered that caffeine binding to one protomer increases the agonist affinity for the other protomer in the A1R homomer, a pharmacological characteristic that correlates with the low caffeine concentrations-induced activation of agonist-promoted A1R signaling. This pharmacological property can explain the biphasic effects reported at low and high concentration of caffeine on locomotor activity.
Subject(s)
Adenosine A1 Receptor Agonists/pharmacology , Adenosine A1 Receptor Antagonists/pharmacology , Caffeine/pharmacology , Cerebral Cortex/drug effects , Nerve Tissue Proteins/metabolism , Neurons/drug effects , Receptor, Adenosine A1/metabolism , Adenosine A1 Receptor Agonists/chemistry , Adenosine A1 Receptor Agonists/metabolism , Adenosine A1 Receptor Antagonists/chemistry , Adenosine A1 Receptor Antagonists/metabolism , Adenosine Deaminase/chemistry , Adenosine Deaminase/metabolism , Allosteric Site/drug effects , Animals , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Caffeine/chemistry , Caffeine/metabolism , Cattle , Cell Membrane/drug effects , Cell Membrane/metabolism , Central Nervous System Stimulants/chemistry , Central Nervous System Stimulants/metabolism , Central Nervous System Stimulants/pharmacology , Cerebral Cortex/cytology , Cerebral Cortex/metabolism , Dimerization , HEK293 Cells , Humans , Kinetics , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Models, Biological , Nerve Tissue Proteins/agonists , Nerve Tissue Proteins/antagonists & inhibitors , Nerve Tissue Proteins/chemistry , Neurons/cytology , Neurons/metabolism , Receptor, Adenosine A1/chemistry , Receptor, Adenosine A1/genetics , Recombinant Fusion Proteins/metabolismABSTRACT
Adenosine A(1) receptor (A(1)AR) agonists have antinociceptive effects in multiple preclinical models of acute and chronic pain. Although numerous A(1)AR agonists have been developed, clinical applications of these agents have been hampered by their cardiovascular side effects. Herein we report a series of novel A(1)AR agonists, some of which are structurally related to adenosine 5'-monophosphate (5'-AMP), a naturally occurring nucleotide that itself activates A(1)AR. These novel compounds potently activate A(1)AR in several orthogonal in vitro assays and are subtype selective for A(1)AR over A(2A)AR, A(2B)AR, and A(3)AR. Among them, UNC32A (3a) is orally active and has dose-dependent antinociceptive effects in wild-type mice. The antinociceptive effects of 3a were completely abolished in A(1)AR knockout mice, revealing a strict dependence on A(1)AR for activity. The apparent lack of cardiovascular side effects when administered orally and high affinity (K(i) of 36 nM for the human A(1)AR) make this compound potentially suitable as a therapeutic.
Subject(s)
Adenosine A1 Receptor Agonists/administration & dosage , Adenosine A1 Receptor Agonists/pharmacology , Adenosine Monophosphate/administration & dosage , Adenosine Monophosphate/pharmacology , Analgesics/administration & dosage , Analgesics/pharmacology , Receptor, Adenosine A1/metabolism , Adenosine A1 Receptor Agonists/chemistry , Adenosine A1 Receptor Agonists/metabolism , Adenosine Monophosphate/chemistry , Adenosine Monophosphate/metabolism , Administration, Oral , Analgesics/chemistry , Analgesics/metabolism , Animals , Behavior, Animal/drug effects , HEK293 Cells , Humans , Male , Mice , Nociception/drug effects , Substrate Specificity , TemperatureABSTRACT
Numerous receptors for ATP, ADP, and adenosine exist; however, it is currently unknown whether a receptor for the related nucleotide adenosine 5'-monophosphate (AMP) exists. Using a novel cell-based assay to visualize adenosine receptor activation in real time, we found that AMP and a non-hydrolyzable AMP analog (deoxyadenosine 5'-monophosphonate, ACP) directly activated the adenosine A(1) receptor (A(1)R). In contrast, AMP only activated the adenosine A(2B) receptor (A(2B)R) after hydrolysis to adenosine by ecto-5'-nucleotidase (NT5E, CD73) or prostatic acid phosphatase (PAP, ACPP). Adenosine and AMP were equipotent human A(1)R agonists in our real-time assay and in a cAMP accumulation assay. ACP also depressed cAMP levels in mouse cortical neurons through activation of endogenous A(1)R. Non-selective purinergic receptor antagonists (pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid and suramin) did not block adenosine- or AMP-evoked activation. Moreover, mutation of His-251 in the human A(1)R ligand binding pocket reduced AMP potency without affecting adenosine potency. In contrast, mutation of a different binding pocket residue (His-278) eliminated responses to AMP and to adenosine. Taken together, our study indicates that the physiologically relevant nucleotide AMP is a full agonist of A(1)R. In addition, our study suggests that some of the physiological effects of AMP may be direct, and not indirect through ectonucleotidases that hydrolyze this nucleotide to adenosine.